Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 2, pp. 184-192
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Oral surveillance and JAK inhibitor safety: the theory of relativity
Kevin Winthrop, Stanley Cohen
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 5, pp. 301-304
Open Access | Times Cited: 148
Rheumatoid arthritis: advances in treatment strategies
Peeyush Prasad, Sneha Verma, Surbhi Gahlot, et al.
Molecular and Cellular Biochemistry (2022) Vol. 478, Iss. 1, pp. 69-88
Closed Access | Times Cited: 113
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 107-118
Open Access | Times Cited: 92
Waiting for JAK inhibitor safety data
Tue Wenzel Kragstrup, Bente Glintborg, Anne-Marie Svensson, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002236-e002236
Open Access | Times Cited: 73
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
Mark Russell, Christopher Stovin, Edward Alveyn, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 8, pp. 1059-1067
Open Access | Times Cited: 72
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Zoltán Szekanecz, Maya H Buch, Christina Charles‐Schoeman, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 101-115
Closed Access | Times Cited: 51
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
Paulina Núñez, Rodrigo Quera, Andrés Yarur
Drugs (2023) Vol. 83, Iss. 4, pp. 299-314
Open Access | Times Cited: 50
JAK inhibitors for rheumatoid arthritis
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 4, pp. 333-344
Closed Access | Times Cited: 43
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 28
Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis
Shivani Mattay, Mohammad Zamani, Dany Saturno, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 5, pp. 961-970.e12
Closed Access | Times Cited: 23
Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study
René Westhovens, Kevin Winthrop, Arthur Kavanaugh, et al.
RMD Open (2025) Vol. 11, Iss. 1, pp. e004857-e004857
Open Access | Times Cited: 1
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
Maurizio Benucci, Arianna Damiani, Maria Infantino, et al.
Pharmacological Research (2022) Vol. 183, pp. 106359-106359
Closed Access | Times Cited: 30
Selective JAK1 inhibitors for the treatment of inflammatory bowel disease
Ole Haagen Nielsen, Theresa Louise Boye, John Gubatan, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108402-108402
Open Access | Times Cited: 22
Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
Robert Harrington, Patricia Harkins, Richard Conway
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6690-6690
Open Access | Times Cited: 21
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
Pablo A. Olivera, Juan S. Lasa, Giovanni Peretto, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1231-1248
Open Access | Times Cited: 20
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester, Jacques‐Eric Gottenberg, Roberto Caporali, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225759
Open Access | Times Cited: 7
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database
Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003885-e003885
Open Access | Times Cited: 5
Novel insights into the management of rheumatoid arthritis: one year in review 2022
Carlo Garaffoni, Antonella Adinolfi, Alessandra Bortoluzzi, et al.
Clinical and Experimental Rheumatology (2022)
Open Access | Times Cited: 22
JAK inhibitors in rheumatology
Kunihiro Yamaoka, Kenji Oku
Immunological Medicine (2023) Vol. 46, Iss. 3, pp. 143-152
Open Access | Times Cited: 12
IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study
Yoichi Nakayama, Ryu Watanabe, Wataru Yamamoto, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 349-357
Closed Access | Times Cited: 11
Start RA treatment – Biologics or JAK-inhibitors?
Roberto Caporali, Sabino Germinario, Dorottya Kacsándi, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 1, pp. 103429-103429
Open Access | Times Cited: 11
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Christina Charles‐Schoeman, Jon T. Giles, Nancy E. Lane, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 1, pp. 157-175
Open Access | Times Cited: 4
Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: a literature review
Olivia Lamberg, Karan Pandher, Jonathon P. Troost, et al.
Archives of Dermatological Research (2024) Vol. 317, Iss. 1
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top